Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 1, 2004, Pages 101-109

  Hedman, Mia ^a   Neuvonen, Pertti J ^a   Neuvonen, Mikko ^a   Holmberg, Christer ^a   Antikainen, Marjatta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CREATINE KINASE; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; TACROLIMUS; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADOLESCENCE; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FECES; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEADACHE; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; LOOSE FECES; MALE; MEASUREMENT; MUSCLE; MUSCLE TENDERNESS; PAIN; PRIORITY JOURNAL; RECIPIENT; SKIN MANIFESTATION; SLEEP DISORDER; TENDON; TENDON TENDERNESS; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZATHIOPRINE; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PRAVASTATIN; TACROLIMUS; TRIGLYCERIDES;

EID: 1642523136     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.011     Document Type: Article

References (31)

1. Johnson D.E., Alderman E.L., Schroeder J.S., Gao S.Z., Hunt S., DeCampli W.M., et al. Transplant coronary artery disease histopathologic correlations with angiographic morphology . J Am Coll Cardiol. 17:1991;449-457.
2. Hertz M.I., Taylor D.O., Trulock E.P., Boucek M.M., Mohacsi P.J., Edwards L.B., et al. The registry of the International Society for Heart and Lung Transplantation nineteenth official report-2002 . J Heart Lung Transplant. 21:2002;950-970.
3. Boucek M.M., Edwards L.B., Keck B.M., Trulock E.P., Taylor D.O., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation fifth official pediatric report-2001 to 2002 . J Heart Lung Transplant. 21:2002;827-840.
4. Schmid C., Kerber S., Baba H.A., Deng M., Hammel D., Scheld H.H. Graft vascular disease after heart transplantation. Eur Heart J. 18:1997;554-559.
5. Kobashigawa J.A., Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation. 63:1997;331-338.
6. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
7. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation. 96:1997;1398-1402.
8. Kobashigawa J.A. Statins as immunosuppressive agents. Liver Transpl. 7:2001;559-561.
9. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 63:2003;12-23.
10. Park J.-W., Siekmeier R., Merz M., Krell B., Harder S., März W., et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 40:2002;439-450.
11. Corpier C.L., Jones P.H., Suki W.N., Lederer E.D., Quinones M.A., Schmidt S.W., et al. Rhabdomyolysis and renal injury with lovastatin use report of two cases in cardiac transplant recipients . JAMA. 260:1988;239-241.
12. Kobashigawa J.A., Murphy F.L., Stevenson L.W., Moriguchi J.P., Kawata N., Kamjoo P., et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation. 82:(Suppl IV):1990;. IV-281-283.
13. Shitara Y., Sugiyama D., Kusuhara H., Kato Y., Abe T., Meier P.J., et al. Comparative inhibitory effects of different compounds on rat oatp1 (slc21a1)- and oatp2 (slc21a5)-mediated transport. Pharm Res. 19:2002;147-153.
14. Holt D.W., Johnston A. Cyclosporin microemulsion. A guide to usage and monitoring. BioDrugs. 7:1997;175-197.
15. Quion J.A., Jones P.H. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet. 27:1994;94-103.
16. Neuvonen P.J., Kantola T., Kivistö K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 63:1998;332-341.
17. Kusuhara H., Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs transporters in the liver, small intestine, brain and kidney . J Control Release. 78:2001;43-54.
18. Regazzi M.B., Iacona I., Campana C., Raddato V., Lesi C., Perani G., et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25:1993;2732-2734.
19. Olbricht C., Wanner C., Eisenhauer T., Kliem V., Doll R., Boddaert M., et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporin-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 62:1997;311-321.
20. Keogh A., Macdonald P., Kaan A., Aboyoun C., Spratt P., Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant. 19:2000;529-537.
21. Penson M.G., Fricker F.J., Thompson J.R., Harker K., Kahler D.A., Schowengerdt K.O. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant. 20:2001;611-618.
22. Hedman M., Neuvonen P.J., Neuvonen M., Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther. 74:2003;178-185.
23. Mulvana D., Jemal M., Pulver S.C. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal. 23:2000;851-866.
24. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
25. Åsberg A. Interactions between cyclosporine and lipid-lowering drugs. Implications for organ transplant recipients. Drugs. 63:2003;367-378.
26. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients are the statin mechanically similar? Pharmacol Ther. 80:1998;1-34.
27. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 35:2001;1096-1107.
28. Omar M.A., Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 36:2002;288-295.
29. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 304:2003;610-616.
30. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 31:2001;469-497.
31. David O.J., Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve review of current algorithms . Ther Drug Monit. 23:2001;100-114.